| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Brief Communications |
1 Division of Nuclear Medicine, Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
2 Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
3 Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania
ABSTRACT
The serotonergic system may play an important role in the pathophysiology of major depressive disorder (MDD). Few imaging studies have examined serotonin transporter (SERT) binding in patients with MDD. We hypothesized that SERT binding activity may be altered in patients with MDD. This study compared SERT binding in patients with MDD with that in healthy controls. Methods: We studied SERT activity in 7 patients (22–50 y old) with moderate to severe MDD and 6 healthy controls (24–56 y old) using 123I-labeled 2-((2-((dimethylamino)methyl) phenyl)thio)-5-iodophenylamine (ADAM) and SPECT brain imaging. Subjects underwent SPECT 4 h after intravenous administration of 185 MBq (5 mCi) of 123I-ADAM. Images were reconstructed in the axial plane, and region-of-interest demarcations were placed on the midbrain, medial temporal region, and basal ganglia region. Results: 123I-ADAM binding to SERT in the midbrain was significantly lower (P = 0.01) in MDD patients (1.81 ± 0.07) than in controls (1.95 ± 0.13). Age-adjusted 123I-ADAM binding in the midbrain correlated significantly with scores on the Hamilton Depression Rating Scale (r = 0.82; P = 0.02). A significant negative correlation was observed between 123I-ADAM SERT binding in the midbrain and age in the healthy control group (r = 0.98; P = 0.0002). SERT binding in the basal ganglia or medial temporal regions of interest did not significantly differ between groups. Conclusion: The findings from this preliminary study suggest the possibility of decreased SERT binding in the midbrain region of patients with MDD, with the degree of decrease correlating with the severity of depressive symptoms. There also appears to be an age-related decline in midbrain 123I-ADAM SERT binding in healthy subjects.
Key Words: depression • serotonin transporter • SPECT • ADAM
This article has been cited by other articles:
|
|
 |
|
  V. G. Frokjaer, L. H. Pinborg, J. Madsen, R. de Nijs, C. Svarer, A. Wagner, and G. M. Knudsen Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans J. Nucl. Med., February 1, 2008; 49(2): 247 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Bhagwagar, N. Murthy, S. Selvaraj, R. Hinz, M. Taylor, S. Fancy, P. Grasby, and P. Cowen 5-HTT Binding in Recovered Depressed Patients and Healthy Volunteers: A Positron Emission Tomography Study With [11C]DASB Am J Psychiatry, December 1, 2007; 164(12): 1858 - 1865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Mao, K. Armstrong, M. A. Bowman, S. X. Xie, R. Kadakia, and J. T. Farrar Symptom Burden Among Cancer Survivors: Impact of Age and Comorbidity J Am Board Fam Med, September 1, 2007; 20(5): 434 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Reneman, M. M. L. de Win, W. van den Brink, J. Booij, and G. J. den Heeten Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects J Psychopharmacol, March 1, 2006; 20(2): 164 - 175. [Abstract] [PDF]
|
|
|
|
|
|
R. Buchert, O. Schulze, F. Wilke, G. Berding, R. Thomasius, K. Petersen, W. Brenner, and M. Clausen Is Correction for Age Necessary in SPECT or PET of the Central Serotonin Transporter in Young, Healthy Adults? J. Nucl. Med., January 1, 2006; 47(1): 38 - 42. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
